Pain Management

Allison Burns discusses how pharmacists should prepare and educate themselves regarding OTC naloxone, and the steps that can be taken in stores and pharmacies to ensure OTC naloxone is visible and available.

Allison Burns, president and CEO of EMO Health, discusses the price point and stigma surrounding OTC naloxone in an interview with Pharmacy Times.

Results show that daily injections of buprenorphine over a 7-day period was safe and well-tolerated in patients who had Clinical Opioid Withdrawal Scale scores of 4 to 7.

In pediatric and adult patients, the top 3 surgical procedures accounted for the highest share of opioid prescriptions, indicating a need for better opioid prescription management and greater awareness of the possible opioid-related adverse events that can stem from prescriptions of the drug.

Roughly one-third of patients with cancer do not achieve adequate pain control.

Early diagnosis and comprehensive treatment may lead to full recovery for patients.

Palliative care may help reduce symptoms and improve quality-of-life for patients with cardiovascular disease.

Expert discusses the challenges faced by pharmacists in palliative and hospice care.

Pharmacists play a crucial role in managing pain for cancer patients in palliative care.

Data analysis can help hospitals address waste of controlled substances that fuels diversion and increased costs.

Speakers at the 2024 Society of Pain and Palliative Care Virtual Conference discussed advanced treatment opportunities for patients with substance use disorder (SUD) and cancer-related pain.

Pharmacists play a key role in psychiatric medication overdose situations

This holistic approach to healing, grounded in harnessing the therapeutic properties of plants, serves as a bridge between centuries-old traditional wisdom and modern scientific practices.

The agency warns consumers against using these products, which are marketed for topical use to relieve pain associated with cosmetic procedures.

Aspirin, known as acetylsalicylic acid, has been marketed in ways that have de-emphasized potential risks to children.

The early phase clinical trial, which ended prematurely in 2013 due to funding challenges, further illustrates disparities in health equity in clinical research.

Clinical pharmacists in the ED are well positioned to facilitate adoption of ED-initiated buprenorphine and improve the treatment of patients with OUD.

Studies have shown that higher expression of CYP2D6 alleles in adults results in excessive production of active metabolites, leading to either therapeutic failure, increased exposure, or more severe adverse effects.

These drugs have interesting mechanisms, unique use, or may support expanded indications in the future.

Tera Moore, PharmD, BCACP, discusses the principles of trauma-informed care, along with the physiologic response to trauma.

Non-expansion states had an increase in prescriptions after PA removal at 27.3% and Medicaid expansion states demonstrated a 22% decrease in prescriptions.

Eligible individuals with opioid use disorder using fentanyl received a single 4 mg dose of transmucosal buprenorphine followed by the extended-release buprenorphine 300 mg injection after approximately 1 hour.

The results suggest that telemedicine could be used to help improve access for other populations that might be stigmatized, beyond hepatitis C virus and opioid use disorder.